MedTrace Logo

The Association Between Primary Aldosteronism and Cognitive Dysfunction

NCT07304674 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2026-01-05

No results posted yet for this study

Summary

The goal of this observational study is to learn about the prevalence, progression, and influencing factors of cognitive impairment in patients with primary aldosteronism (PA). The main questions it aims to answer are:

1. What is the prevalence of baseline cognitive impairment in PA patients and what factors are associated with it?
2. What is the incidence of cognitive progression in PA patients within 1 and 5 years of follow-up and what factors influence this progression? Participants who are already diagnosed with PA as part of their regular medical care will be invited to join this long-term study. They will complete regular cognitive tests, medical check-ups, and questionnaires for up to 5 years. Some participants will also have optional blood tests and brain scans to help researchers understand the causes behind any cognitive changes.

Conditions

  • Primary Aldosteronism
  • Cognitive Dysfunction
  • Mild Cognitive Impairment (MCI)
  • Dementia

Sponsors & Collaborators

  • Xinjiang Medical University

    lead OTHER

Principal Investigators

  • Xiang Xie, PhD · First Affiliated Hospital of Xinjiang Medical University

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-31
Primary Completion
2030-12-31
Completion
2031-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07304674 on ClinicalTrials.gov